To see more information:

Andrus Tasa

Corporate business media and news feed
Laboratories, Research Institutions, State and Society

TBD PHARMATECH OÜ's activity report 2022

The main activity of TBD Pharmatech is fine chemistry and synthesis services and small-scale production of active pharmaceutical ingredients. The company's main customers are chemical, pharmaceutical and biotechnology companies in Europe, as well as in Switzerland and Israel. The company has invested a lot in the design of its own product portfolio in recent years. The company's product portfolio includes over 30 active pharmaceutical ingredients and fine chemical products. TBD Pharmatech's sales revenue for 2022 was 5.17 million euros. The company's main income came from the provision of

Dropdown

all articles

KALTEC OÜ: Tax Debt and Loss of Trust

Attention!  KALTEC OÜ has faced serious consequences due to the accumulation and neglect of tax debts, including loss of credibility and possible legal actions.
ssb.ee
Attention! KALTEC OÜ has faced serious consequences due to the accumulation and neglect of tax debts, including loss of credibility and possible legal actions. Failure to fulfill tax obligations not only affects the company’s financial situation but may also hinder further cooperation with partners. 📌 Total damage to the tax collector: 772,05 EUR. The company’s management at the time of the debts included Andrus Tasa , who started in business 28 years ago at the age of 31. The total turnover of the companies led by them in 2024 was 14.39 million EUR , while the average gross salary of

Are you sure you want to delete this article?

Loader

Loader

App Ad

Scorestorybook Chrome extension

The Storybook extension tells you which company's website you are currently on and how reliable that company is today. download extension

See the background of the caller! Storybook App brings you direct contacts for 400,000 Estonian companies and individuals (managers, officials). The data is enriched with solvency and financial information.